Riddhi Siddhi Gluco Biols Ltd is Rated Strong Sell

Understanding the Current Rating

The Strong Sell rating assigned to Riddhi Siddhi Gluco Biols Ltd indicates a cautious stance for investors, signalling significant concerns across multiple evaluation parameters. This rating is based on a comprehensive assessment of the company’s quality, valuation, financial trend, and technical outlook. It serves as a guide for investors to consider the risks involved before committing capital to this stock.

Quality Assessment

As of 02 April 2026, the company’s quality grade remains below average. This reflects ongoing operational challenges, including sustained losses and weak profitability metrics. The company’s ability to generate returns on capital employed (ROCE) is negative, underscoring inefficiencies in deploying shareholder funds. Additionally, the EBIT to interest coverage ratio stands at a concerning -1.04, indicating difficulties in servicing debt obligations. Such weak fundamentals highlight structural issues that weigh heavily on the stock’s outlook.

Valuation Perspective

Currently, Riddhi Siddhi Gluco Biols Ltd is classified as risky from a valuation standpoint. The stock trades at levels that do not justify its financial performance, with negative EBITDA of ₹-7.68 crores reported recently. This negative earnings before interest, taxes, depreciation, and amortisation figure signals operational losses that erode investor value. The stock’s historical valuations have been more favourable, but the latest data shows a deterioration, making it less attractive relative to peers and market benchmarks.

Financial Trend Analysis

The financial trend for the company is very negative as of today. Net sales have declined by 9.59% in the latest reported period, with a sharp 22.58% drop over the last six months to ₹72.18 crores. Profit after tax (PAT) has contracted by 73.52% to ₹13.69 crores in the same timeframe, while interest expenses have surged by 47.94% to ₹9.32 crores, further pressuring margins. The company has reported losses for four consecutive quarters, reflecting persistent operational difficulties and a challenging business environment.

Technical Outlook

From a technical perspective, the stock is bearish. Despite a modest 2.61% gain on the day of analysis and a 7.10% year-to-date increase, the stock has underperformed the broader market over the past year. While the BSE500 index declined by 4.14% in the last 12 months, Riddhi Siddhi Gluco Biols Ltd’s stock fell by 18.03%, signalling weaker investor sentiment and downward momentum. The technical grade reflects this trend, suggesting limited near-term upside potential.

Stock Returns and Market Performance

As of 02 April 2026, the stock’s returns over various periods illustrate its volatile and challenging performance. It recorded a 1-day gain of 2.61% and a 1-week increase of 4.24%, but these short-term gains are offset by longer-term declines. The 1-month return is down 4.96%, 3-month return is marginally negative at -0.44%, and the 6-month return shows a steep fall of 19.00%. Over the past year, the stock has delivered a negative return of 18.03%, significantly underperforming the broader market indices.

Implications for Investors

The Strong Sell rating signals that investors should exercise caution with Riddhi Siddhi Gluco Biols Ltd. The combination of weak quality metrics, risky valuation, deteriorating financial trends, and bearish technical indicators suggests that the stock carries elevated risk. Investors seeking capital preservation or growth may find more favourable opportunities elsewhere, given the company’s current challenges and market underperformance.

Summary of Key Metrics as of 02 April 2026

• Mojo Score: 1.0 (Strong Sell)
• Market Capitalisation: Microcap segment
• Operating Losses: Negative EBITDA of ₹-7.68 crores
• Net Sales Decline: -9.59% latest period; -22.58% over six months
• PAT Decline: -73.52% over six months to ₹13.69 crores
• Interest Expense Increase: +47.94% to ₹9.32 crores
• Stock Returns: 1Y return of -18.03%, underperforming BSE500’s -4.14%

Contextualising the Rating

It is important to note that the rating was last updated on 01 Feb 2025, reflecting a reassessment of the company’s prospects at that time. However, the financial and market data presented here are current as of 02 April 2026, providing a real-time snapshot of the company’s position. This distinction ensures investors understand that the rating is based on a comprehensive evaluation, while the latest figures offer insight into ongoing performance and risks.

Sector and Market Considerations

Riddhi Siddhi Gluco Biols Ltd operates within the Trading & Distributors sector, a segment that can be sensitive to economic cycles and market demand fluctuations. The company’s microcap status adds an additional layer of volatility and liquidity risk. Compared to broader market indices and sector peers, the stock’s performance and financial health remain subdued, reinforcing the cautious stance advised by the current rating.

Investor Takeaway

For investors, the Strong Sell rating serves as a warning to carefully evaluate the risks before considering exposure to Riddhi Siddhi Gluco Biols Ltd. The company’s ongoing losses, weak debt servicing ability, declining sales, and negative market momentum suggest that capital preservation should be prioritised. Monitoring future quarterly results and any strategic changes will be essential to reassess the stock’s outlook.

Conclusion

In summary, Riddhi Siddhi Gluco Biols Ltd’s current Strong Sell rating by MarketsMOJO reflects significant challenges across quality, valuation, financial trend, and technical dimensions. As of 02 April 2026, the company continues to face operational and market headwinds that justify a cautious approach. Investors are advised to consider these factors carefully in their portfolio decisions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today